LY 274614

Drug Profile

LY 274614

Latest Information Update: 02 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antiepileptic drugs; Isoquinolines; Neuroprotectants; Small molecules
  • Mechanism of Action Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Epilepsy; Huntington's disease; Neurological disorders; Parkinson's disease

Most Recent Events

  • 02 Oct 2000 No-Development-Reported for Alzheimer's disease in USA (PO)
  • 02 Oct 2000 No-Development-Reported for Epilepsy in USA (PO)
  • 02 Oct 2000 No-Development-Reported for Huntington's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top